Compare Gilead Sciences, Inc. (GILD) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Prudential PLC — how do they compare? Gilead Sciences, Inc. trades at $132.98 (market cap $163.51B), while Prudential PLC trades at $28.75 (market cap $35.24B). The key difference: Gilead Sciences, Inc. is far larger — about 4.6× Prudential PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | PUK | |
|---|---|---|
Market Cap | $163.51B | $35.24B |
Sector | Health | Financials |
52-Week High | $155.80 | $33.61 |
52-Week Low | $108.22 | $24.65 |
Enterprise Value | $178.05B | $36.68B |
Dividend Yield | 2.49% | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Prudential PLC (PUK) trades at $28.59, up 0.67% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.47, net margin of 14.52%, and ROE of 21.15%. Recent earnings have beaten expectations in two of the last three quarters. Analyst consensus is positive with 50% buy ratings, though recent news highlights regulatory challenges in China and Japan that have pressured the stock.
The outlook is mixed: attractive valuation and profitability metrics support upside, while regulatory headwinds in key Asian markets and overbought technical indicators near-term pose risks. The company's strategic repositioning in India and strong cash flow generation provide balance to the investment case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
